About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
Updates on Myeloproliferative Neoplasms Including CML
By
Winship Cancer Institute - Emory University
FEATURING
Anthony Hunter
By
Winship Cancer Institute - Emory University
FEATURING
Anthony Hunter
0 views
May 7, 2024
Comments
0
Login to view comments.
Click here to Login
Featured Video
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
Featured Video
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
Recommended
AUTOPLAY
ON
Related
Newest
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
08:44
American Contact Dermatitis Society (ACDS)
What to Do When Patch Testing is Negative?
Feat.
M. Montanez-Wiscovich
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
04:16
Luke Fletcher
Efficacy and Safety of Asciminib in Ph+ CML
08:18
Insights from 2023 ASH Annual Meeting
Treatment Strategies for Hematocrit Control in PV
Feat.
A. Zhou
09:51
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
Feat.
N. S. Raje
23:35
University of Colorado Division of Hematology
2024 Updates in PV/ET
Feat.
B. McMahon
24:27
BMFcases
Experts Discuss Pros and Cons of Treatment Approaches in PV
Feat.
T. Bat,
A. Tefferi
27:49
Insights from 2024 EHA Annual Meeting
AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024
Feat.
T. Badar
27:37
Indy Hematology Review
Review of Myeloproliferative Neoplasms
Feat.
A. Tefferi
18:04
Ruben Mesa
Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…
17:05
BMFcases
Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…
Feat.
T. Bat,
A. Tefferi
07:55
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes …
Feat.
E. Atallah
06:18
Cleveland Clinic Taussig Cancer Institute
SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…
Feat.
A. Gerds
23:15
Rush University Medical Center
Is Post-HSCT Maintenance the SOC for AML?
Feat.
M. Levis
10:02
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…
Feat.
R. Mesa
21:52
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…
Feat.
D. Tremblay
05:20
Prithviraj Bose
When to Switch From Hydroxyurea to Ruxolitinib in PV
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
